GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Nerandomilast - JASCAYD tablets

Local official-label summaryBase record retrieved 2026-09-08See the evidence for this drug2 sources available - open source summaries, references and comparisons

JASCAYD / Nerandomilast

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
JASCAYD: official guidance does not repair the RX rendering

The RX card is PK-only. The August 2026 official label separately supplies renal prescribing guidance and an ESRD restriction.

Before applying: Use the official section for prescribing scope while keeping the incomplete RX source flagged; neither is an independent validation of the same label.

Also check: JASCAYD: official guidance does not repair the RX rendering

Official source

Nerandomilast - JASCAYD official label

Product / population
Nerandomilast - JASCAYD official label; selected source sections, not a full prescribing monograph.
Renal measure
eGFR, mL/min/1.73 m2; retain body-surface-area indexing. CKD-EPI is named.

Renal dosing, restrictions and evidence limits

Section 8.6 recommends the same dosage as normal renal function for mild (eGFR >=60 to <90), moderate (>=30 to <60) and severe (>=15 to <30) impairment, in mL/min/1.73 m2 with CKD-EPI specified. ESRD below 15 has not been investigated and use is not recommended. This selected renal guidance does not replace the product dosage, tolerability, interaction or indication instructions. It is separate official-label content, not an additional independent clinical study.

Source revision: Prescribing information revised 08/2026. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa1b14c6-957f-d326-5099-911bfe33e391

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Nerandomilast - JASCAYD official label

No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Nerandomilast - JASCAYD official label; selected source sections, not a full prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2; retain body-surface-area indexing. CKD-EPI is named.
Retrieved: 2026-09-08

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - JASCAYD

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Nerandomilast - JASCAYD tablets; selected source sections, not a full prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2; retain body-surface-area indexing. CKD-EPI is named.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

JASCAYD: official guidance does not repair the RX rendering

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope

JASCAYD: official guidance does not repair the RX rendering

The RX card is PK-only. The August 2026 official label separately supplies renal prescribing guidance and an ESRD restriction.

How to use this: Use the official section for prescribing scope while keeping the incomplete RX source flagged; neither is an independent validation of the same label.

GlobalRPh RX List - JASCAYDNerandomilast - JASCAYD official label

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeNerandomilast - JASCAYD official labelGlobalRPh RX List - JASCAYD
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/jascayd-drug/

Exact product and population

Nerandomilast - JASCAYD tablets; selected source sections, not a full prescribing monograph.

RDM48-SCOPE-nerandomilast-jascayd · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Nerandomilast - JASCAYD official label

Open original reference

Open / share this exact local source

DailyMed / Boehringer Ingelheim Pharmaceuticals, Inc. · Nerandomilast - JASCAYD official label; selected source sections, not a full prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2; retain body-surface-area indexing. CKD-EPI is named.
Source date: Prescribing information revised 08/2026.
Retrieved: 2026-09-08

No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Section 8.6 recommends the same dosage as normal renal function for mild (eGFR >=60 to <90), moderate (>=30 to <60) and severe (>=15 to <30) impairment, in mL/min/1.73 m2 with CKD-EPI specified. ESRD below 15 has not been investigated and use is not recommended. This selected renal guidance does not replace the product dosage, tolerability, interaction or indication instructions. It is separate official-label content, not an additional independent clinical study.

RDM48-official-nerandomilast-jascayd-cdf5d3150c-C1 · Source locator: Prescribing information 8.6; 12.3; revision in highlights.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa1b14c6-957f-d326-5099-911bfe33e391
Retrieved
2026-09-08
Exact label title
Nerandomilast - JASCAYD official label
DailyMed Set ID
fa1b14c6-957f-d326-5099-911bfe33e391
Labeler
Boehringer Ingelheim Pharmaceuticals, Inc.
DailyMed page updated
2026-08-14
Label revision
Prescribing information revised 08/2026.
Archive publication date
2026-08-31
SPL version
6
Renal-function method
eGFR, mL/min/1.73 m2; retain body-surface-area indexing. CKD-EPI is named.
Source date/version
Prescribing information revised 08/2026.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
0b72d7707b979fb920e8aea0be205fa65b349aeb1edd03fa28c85775166d67d2
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - JASCAYD

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Nerandomilast - JASCAYD tablets; selected source sections, not a full prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2; retain body-surface-area indexing. CKD-EPI is named.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The retrieved pharmacokinetic section reports no clinically significant exposure difference with mild, moderate or severe renal impairment, down to eGFR 15 to <30 mL/min/1.73 m2 using CKD-EPI categories. ESRD was not studied. The referenced renal prescribing subsection was not present in this returned RX rendering. This card stores selected pharmacokinetic evidence only; the separate official card supplies prescribing guidance and is not a repair of the RX page.

RDM48-rxlist-nerandomilast-jascayd-cc3dc19c5e-C1 · Source locator: Clinical Pharmacology: Specific Populations, lines 155-157.

Source-specific limits

Limited RX section; do not infer prescribing instructions from unchanged exposure.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/jascayd-drug/
Retrieved
2026-09-08
Renal-function method
eGFR, mL/min/1.73 m2; retain body-surface-area indexing. CKD-EPI is named.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
96bc2257668d2d1cfb037b5e0df0104d0ab66e426e50b41d25f4284c211ff37b

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/jascayd-drug/
Source retrieval
2026-09-08. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
1f0dc69a061599ca36c6fc40dd52d7db7f2f2ee13f5acd44414e8548b38be22f
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report